Ocular Therapeutix, Inc.
OCUL
Positions held
Your positionsOCUL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Ocular Therapeutix operates in the biotechnology sector, focusing on innovative therapies for eye diseases, which positions it well in a growing industry with increasing demand for specialized treatments.
- The company has a strong recommendation of 'strong_buy' from analysts, indicating positive investor sentiment.
- Ocular's revenue increased by 25% compared to the prior quarter, reaching $13 million.
- The company's operating margin is significantly negative at -609.3%, indicating ongoing financial struggles.
- Ocular's net income for the most recent quarter was -$78.763 million, reflecting continued losses.
- The stock has a 'Strong Sell' signal with a score of -24.00, suggesting bearish market sentiment.
Fundamentals
| Market cap | $1.65B | Enterprise value | $1.13B | Trailing P/E | — | Forward P/E | -5.17 |
| PEG | — | Price / book | 3.17 | Beta | 0.99 | Dividend yield | 0.00% |
| Revenue growth | 0.1% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -6.1% |
| Profit margin | 0.0% | ROE | -73.0% | ROA | -35.0% | Debt / equity | 0.15 |
| Current ratio | 13.11 | Free cash flow | -$159.25M | Analyst recommendation | strong_buy | Mean target | $27.09 |
| 52w high | $16.44 | 52w low | $6.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $13.5M | $10.8M | $13.3M | $14.5M | $13.5M | — |
| Op margin | -609.3% | -865.5% | -526.5% | -472.3% | -502.6% | — |
| Net income | -$78.8M | -$88.6M | -$64.7M | -$69.4M | -$67.8M | — |
| Gross margin | 85.1% | 87.7% | 88.0% | 87.8% | 85.6% | — |
| Gross profit | $11.5M | $9.5M | $11.7M | $12.8M | $11.5M | — |
| Operating income | -$82.1M | -$93.3M | -$69.8M | -$68.7M | -$67.6M | — |
- Revenue +25% vs prior quarter ($13M vs $11M).
- Gross margin 85.1% (was 87.7% prior quarter).
- Operating margin expanded to -609.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | — |
| Op margin | -519.8% | -269.6% | -141.0% | -152.7% | — |
| Net income | -$266M | -$194M | -$80.7M | -$71.0M | — |
| Gross margin | 87.3% | 91.2% | 91.0% | 91.2% | — |
| Gross profit | $45.4M | $58.1M | $53.2M | $47.0M | — |
| Operating income | -$270M | -$172M | -$82.4M | -$78.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Top 4 Healthcare Stocks Backed by Raymond James Analysts
2026-10-05 · 3 Stocks Under $10 That Fall Short
2026-10-05 · Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
2026-10-02 · Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny
2026-10-02 · 3 of Wall Street’s Favorite Stocks That Fall Short
2026-10-01 · OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
2026-10-01 · 3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
2026-10-01 · Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
2026-09-28 · OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-23 · Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
2026-09-23 · Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
2026-09-23 · Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Price (daily)
Full chart · RSI · MACD · patterns